Evidence map›Paper›PMID 36273198›Full record

ArticleBiomaterials research2022

Targeted thrombolysis by magnetoacoustic particles in photothrombotic stroke model.

Wonseok Choi, Hyeyoun Cho, Gahee Kim, Inchan Youn, Jaehong Key, Sungmin Han

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Wonseok ChoiBiomedical Research Division, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Hyeyoun ChoDepartment of Biomedical Engineering, Yonsei University, Wonju, Republic of Korea.
Gahee KimDepartment of Biomedical Engineering, Yonsei University, Wonju, Republic of Korea.
Inchan YounBiomedical Research Division, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Jaehong KeyDepartment of Biomedical Engineering, Yonsei University, Wonju, Republic of Korea. jkey@yonsei.ac.kr.
Sungmin HanBiomedical Research Division, Korea Institute of Science and Technology, Seoul, Republic of Korea. han0318@kist.re.kr.ORCID http://orcid.org/0000-0003-2762-668X
Yonsei University · KRKorean Association Of Science and Technology Studies · KRKyung Hee University · KR

Funding

Korean National Police Agency 220222M0303Ministry of Trade, Industry and Energy 20014477National Research Council of Science and Technology CAP-18014-000National Research Foundation of Korea 2018R1D1A1B07042339 and 2019K2A9A2A08000123.
6 · The paper itself

Abstract

backgroundRecombinant tissue plasminogen activator (rtPA) has a short half-life, and additional hemorrhagic transformation (HT) can occur when treatment is delayed. Here, we report the design and thrombolytic performance of 3 [Formula: see text]m discoidal polymeric particles loaded with rtPA and superparamagnetic iron oxide nanoparticles (SPIONs), referred to as rmDPPs, to address the HT issues of rtPA.

methodsThe rmDPPs consisted of a biodegradable polymeric matrix, rtPA, and SPIONs and were synthesized via a top-down fabrication.

resultsThe rmDPPs could be concentrated at the target site with magnetic attraction, and then the rtPA could be released under acoustic stimulus. Therefore, we named that the particles had magnetoacoustic properties. For the in vitro blood clot lysis, the rmDPPs with magnetoacoustic stimuli could not enhance the lytic potential compared to the rmDPPs without stimulation. Furthermore, although the reduction of the infarcts in vivo was observed along with the magnetoacoustic stimuli in the rmDPPs, more enhancement was not achieved in comparison with the rtPA. A notable advantage of rmDPPs was shown in delayed administration of rmDPPs at poststroke. The late treatment of rmDPPs with magnetoacoustic stimuli could reduce the infarcts and lead to no additional HT issues, while rtPA alone could not show any favorable prognosis.

conclusionThe rmDPPs may be advantageous in delayed treatment of thrombotic patients.

Indexed as

Controlled Release Drug CarriersIschemic StrokePhotothrombosisRecombinant Tissue Plasminogen Activator (rtPA)Thrombolysis

Identifiers

PMID36273198
PMCPMC9587564
OpenAlexW4307135229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.